Alfonso Gómez de Liaño

5PUBLICATIONS
32CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPacific Peoples medicine and treatments
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Sep 28, 2026
Prognostic value of PD-L1 in patients with metastatic renal cell carcinoma (mRCC) treated with antiangiogenic first line drugs (PROANG-SOGUG study).

|Jul 22, 2026
Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer.

|Oct 29, 2025
Sarcomatoid Differentiation in Renal Cell Carcinoma: Clinical and Pathologic Heterogeneity and Outcomes With Immune Checkpoint Inhibitors-Data From the ARON-1 Study.

Francesco Massari, Matteo Rosellini, Bohuslav Melichar

|Mar 29, 2023
First Evidence of Activity of Enfortumab Vedotin on Brain Metastases in Urothelial Cancer Patients.

Christof Vulsteke, Laurens De Cocker, Alfonso Gómez de Liaño

|Jan 18, 2021
Patient Perspective on the Management of Cancer Pain in Spain.

Jesús García-Foncillas, Antonio Antón-Torres, Fernando Caballero-Martínez

Pageof 1

Frequent Collaborators

2 joint publications

Javier Molina-Cerrillo

1 joint publications

Francesco Massari

1 joint publications

Matteo Rosellini

1 joint publications

Enrique Grande